Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial

Rafael E. de Feria Cardet\textsuperscript{a}, Michael S. Hofman\textsuperscript{b,c}, Tatiana Segard\textsuperscript{d}, Jackie Yim\textsuperscript{a}, Scott Williams\textsuperscript{b,c,e,f,g}, Roslyn J. Francis\textsuperscript{d,h}, Mark Frydenberg\textsuperscript{i,j}, Nathan Lawrentschuk\textsuperscript{b,k,l,m}, Declan G. Murphy\textsuperscript{b,c,m}, Richard De Abreu Lourenc\textsuperscript{o,\!*}

\textsuperscript{a}Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia; \textsuperscript{b}Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; \textsuperscript{c}Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; \textsuperscript{d}Sir Charles Gairdner Hospital, Perth, Australia; \textsuperscript{e}Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; \textsuperscript{f}Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Camperdown, Australia; \textsuperscript{g}Department of Medicine, University of Queensland, Brisbane, Australia; \textsuperscript{h}School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia; \textsuperscript{i}Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia; \textsuperscript{j}Cabrini Institute, Cabrini Health, Malvern, Australia; \textsuperscript{k}Department of Surgery, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; \textsuperscript{l}Ej Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Australia; \textsuperscript{m}Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia

Abstract

**Background:** Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) into routine care, it is important to assess if the benefits justify the differences in resource use.

**Objective:** To determine the cost-effectiveness of PSMA-PET/CT when compared with conventional imaging.

**Design, setting, and participants:** A cost-effectiveness analysis was developed using data from the proPSMA study. proPSMA included patients with high-risk prostate cancer assigned to conventional imaging or \(^{68}\)Ga-PSMA-11 PET/CT with planned health economics data collected. The cost-effectiveness analysis was conducted from an Australian societal perspective.

**Intervention:** \(^{68}\)Ga-PSMA-11 PET/CT compared with conventional imaging (CT and bone scan).

**Outcome measurements and statistical analysis:** The primary outcome from proPSMA was diagnostic accuracy (nodal and distant metastases). This informed a decision tree analysis of the cost per accurate diagnosis.

**Results and limitations:** The estimated cost per scan for PSMA PET/CT was AUD\$1203, which was less than the conventional imaging cost at AUD\$1412. PSMA PET/CT was thus dominant, having both better accuracy and a lower cost. This resulted in a cost of AUD \$959 saved per additional accurate detection of nodal disease, and AUD\$1412 saved for additional accurate detection of distant metastases. The results were most sensitive to variations in the number of men scanned for each \(^{68}\)Ga-PSMA-11 production run. Subsequent research is required to assess the long-term costs and benefits of PSMA PET/CT-directed care.

* Corresponding author. Centre for Health Economics Research and Evaluation, University of Technology Sydney, P.O. Box 123, Haymarket, NSW 2007, Australia. Tel. +61 2 95144729, Fax: +61 2 95144730. E-mail address: richard.deabreulourenc@chere.uts.edu.au (R. De Abreu Lourenc\textsuperscript{o}).
1. Introduction

Radiolabelled small molecules targeting prostate-specific membrane antigen (PSMA) with positron emission tomography (PET) allow whole-body imaging for detection of prostate cancer spread [1]. The proPSMA randomised controlled trial (RCT) recently provided high-level evidence of superior diagnostic accuracy of PSMA PET/computed tomography (CT) compared with conventional imaging (CI; CT of the abdomen/pelvis and bone scanning) for detection of metastatic disease [2]. It showed that 68Ga-PSMA-11 PET/CT was more sensitive and specific at detecting pelvic lymph-node and distant metastatic disease in men with high-risk prostate cancer who are being considered for prostatectomy or radiotherapy.

Before integrating PSMA PET/CT into routine care, it is important to assess whether the additional benefits are justified by potential differences in the use of resources required for its implementation. This paper assesses the costs and outcomes (diagnostic accuracy) associated with the use of PSMA PET/CT compared with CI in staging men with high-risk prostate cancer using information collected as part of the proPSMA study.

2. Patients and methods

The design and conduct of the proPSMA study has been reported elsewhere [2]. In brief, proPSMA allocated high-risk prostate cancer patients being considered for prostatectomy or radiotherapy to first-line imaging with PSMA PET/CT or CI. The primary outcome was diagnostic accuracy using a predefined criterion encompassing histopathology, temporal changes in imaging, and biochemical determined at the 6-month patient follow-up visit.

The population in the proPSMA study and subsequent economic analysis was high-risk prostate cancer patients, defined by PSA ≥ 20 ng/ml or International Society of Urological Pathology grade group 3–5 or clinical stage ≥ T3.

All sites participating in proPSMA were prospectively surveyed to provide information on 68Ga-PSMA production, including whether purchased or manufactured in-house (Supplementary Table 1). For in-house manufacture, details were collected on specific consumables (including the gallium generator and cartridges or kit), equipment items (including the automated synthesis unit and high-performance liquid chromatography system), staff time for production and quality assurance (QA), and the dose (MBq) of radiopharmaceutical manufactured per production run.

Conclusions: PSMA PET/CT has lower direct comparative costs and greater accuracy compared to conventional imaging for initial staging of men with high-risk prostate cancer. This provides a compelling case for adopting PSMA PET/CT into clinical practice.

Patient summary: The proPSMA study demonstrated that prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) better detects disease that has spread beyond the prostate compared with conventional imaging. Our analysis shows that PSMA PET/CT is also less costly than conventional imaging for the detection of disease spread.

This research was presented at the European Association of Nuclear Medicine Scientific Meeting in October 2020.

© 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Combining the cost per scan with the accuracy of detection, PSMA PET/CT would be dominant, as it is less costly and more accurate. Focusing on the accuracy of detection for each metastasis type separately, PSMA PET/CT was associated with AUD$959 saved per additional accurate detection of nodal disease compared with CI, and AUD$1412 saved per additional accurate detection of distant metastases. When weighted by the probability of metastasis detection as observed in proPSMA, and including the accuracy of detection for all possible metastatic states, the dominance of PSMA PET/CT resulted in a cost saving of AUD$428 per additional accurate diagnosis.

The weighted cost per metastasis detection was sensitive to the number of patients per elution and the cost components of both imaging techniques (Fig. 2). Assuming on one patient per $^{68}$Ga-PSMA elution resulted in an incremental cost per additional case detected for Ga-PSMA compared with CI of AUD$2553 for nodal disease and AUD $3758 for metastatic disease, for a weighted cost per accurate diagnosis of AUD$1138. However, if three patient doses were obtained per elution, AUD$950 would be saved for an additional accurate diagnosis.

4. Discussion

This is the first economic evaluation to directly use data from a large RCT that demonstrated the superior accuracy of PSMA PET/CT in this setting. Our analysis indicates that PSMA PET/CT is dominant to CI in the short-term for staging men with high-risk disease, as it has greater diagnostic accuracy and is cheaper than CI.

Altering the detection of metastatic disease has implications for the downstream treatment of prostate cancer in terms of both health care service use and the impact on quality of life [6]. More accurate diagnosis of metastatic disease through the use of PSMA PET/CT is likely to result in more men receiving appropriate treatment for metastases, and thus not incurring the costs, lower survival, or poorer quality of life associated with an incorrect diagnosis. This is an important implication of this analysis that will require

---

**Table 1 – proPSMA key results informing the economic evaluation.**

<table>
<thead>
<tr>
<th></th>
<th>$^{68}$Ga-PSMA PET/CT (n = 145)</th>
<th>Conventional imaging (n = 150)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distant metastases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity, % (95% confidence interval)</td>
<td>92 (81–100)</td>
<td>54 (34–74)</td>
</tr>
<tr>
<td>Specificity, % (95% confidence interval)</td>
<td>99 (98–100)</td>
<td>93 (88–97)</td>
</tr>
<tr>
<td>Nodal metastases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity, % (95% confidence interval)</td>
<td>83 (70–95)</td>
<td>23 (10–35)</td>
</tr>
<tr>
<td>Specificity, % (95% confidence interval)</td>
<td>99 (97–100)</td>
<td>96 (93–100)</td>
</tr>
<tr>
<td>Scan duration (h)</td>
<td>1.51</td>
<td>5.52*</td>
</tr>
</tbody>
</table>

CT = computed tomography; PET = positron emission tomography; PSMA = prostate–specific membrane antigen.

* The scan time for conventional imaging includes 47 min for acquisition of a bone scan with single–photon emission CT/CT and 15 min for acquisition of a CT scan.

---

revisiting as the implementation of PSMA PET/CT scanning, and its implications for the management of men with prostate cancer, continues to be monitored.

There have been other analyses of the potential cost-effectiveness of PSMA PET/CT [7,8]. These studies were in different clinical settings, such as men who had castrate-resistant disease [8] or postprostatectomy lymph node dissection [7]. Scholte et al [7] focused exclusively on men with existing nodal disease, while the balance of nodal and distant metastases in the population in the study by Gordon et al [8] was not reported. Our analysis shows superiority of PSMA PET/CT over CI in the detection of both nodal and distant metastases. Similarly, PSMA PET/CT accuracy in those papers was based on assumptions from the literature or small case series. A similar cohort-based analysis considered the cost implications of shifting between the use of 11C-choline PET/CT or CI and PSMA PET/CT and found that if each additional PSMA PET/CT procedure added US $1466 or US$4312, respectively, the procedure would be considered cost-effective [9].

Our analysis differed in that key inputs were defined prospectively at the commencement of proPSMA [10], allowing us to reflect resource use within the study. Importantly, this included aspects of producing PSMA radiotracers that have been cited as being important contributors to cross-organisation and jurisdictional differences in the costs of providing such scans [11,12]. Our data collection included the patient impact of differences in the time required to administer the required tracers and to acquire scans. This demonstrated a significant difference in favour of PSMA PET/CT, even when the costs of attending hospital on separate days for acquisition of CT and bone scans were not considered.

The sensitivity analysis showed that the weighted cost per metastasis detection for 68Ga-PSMA PET/CT was sensitive to the number of patients per elution. On the basis of the yields obtained per synthesis, between two and three patient doses could be regularly obtained. Clinical demand for PSMA PET/CT is likely to be high given the known incidence of prostate cancer, and our assumption of more than one patient dose per elution is therefore clinically applicable [11] and supports the dominance of PSMA PET/CT over CI.

The health resources identified are based on the proPSMA study and hence reflect the Australian clinical and institutional setting. Here, as in many European countries, gallium-68 generators can be used on site to produce the PSMA radioisotope [13,14]. By contrast, the USA has a centralised market for radiotracers, which may lead to differences in the use of resources and costs [15]. Our results were sensitive to the efficiency of the generator and associated costs, suggesting they may be generalisable to European countries with local on-site production that may reflect similar production efficiencies.

4.1. Limitations

Our costings are specific to the use of 68Ga-PSMA-11 largely manufactured on site in hospital radiopharmacies. Further research is needed to confirm whether our results apply in other settings or indeed how the cost-effectiveness of PSMA PET/CT might alter in response to the radiopharmaceutical utilised [11]. Several other proprietary PSMA-targeting radiopharmaceuticals have been adopted clinically, including 18F-DCFPyL and 18F-PSMA-1007. These have potential for large-scale production and distribution, which could further reduce costs. The costs related to the proprietary nature of these ligands and production in compliance with good manufacturing practice, however, could alter this benefit. Although there are relatively minor differences, the largest volume of literature and experience is for 68Ga-PSMA-11, and more data are required to confirm the performance of 18F-labelled ligands. Advances with 68Ga-PSMA-11 include kit-based production to increase efficiency [16] and cyclotron 68Ga production that allows large-scale production analogous to 18F [17]. Finally, it is important that subsequent research places the superiority of PSMA PET/
CT for disease staging in context for the longer-term costs and outcomes of prostate cancer treatment.

5. Conclusions

PSMA PET/CT is dominant, with both lower direct comparative costs and greater accuracy when compared with CI for the detection of metastatic disease in men with high-risk prostate cancer. Combined with the other findings from proPSMA for patient management change, lower radiation exposure, and fewer equivocal findings, a compelling case can be made for adopting PSMA PET/CT.

Author contributions: Richard De Abreu Lourengo had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: de Feria Cardet, De Abreu Lourengo, Hofman, Frydenberg, Williams.

Acquisition of data: Hofman, de Feria Cardet, Segard, De Abreu Lourengo.

Analysis and interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: de Feria Cardet, De Abreu Lourengo, Segard.

Obtaining funding: De Abreu Lourengo.

Administrative, technical, or material support: None.

Supervision: De Abreu Lourengo.

Other (validation of the model parameters): Hofman, Lawrentschuk, Williams.

Financial disclosures: Richard De Abreu Lourengo certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Michael S. Hofman reports grants from Prostate Cancer Foundation of Australia, Movember, and the Peter MacCallum Foundation during the conduct of the proPSMA study; other grants from Prostate Cancer Foundation, the US Department of Defense, and the Victorian Cancer Agency; and personal fees and nonfinancial support from Ipsen, Sanofi, Genzyme, and Jannsen outside the submitted study. Declan G. Murphy reports personal fees from Astellas, Janssen, Bayer, Ferring, and Ipsen outside of the submitted work. The remaining authors have nothing to disclose.

Funding/Support and role of the sponsor: This investigator-initiated trial was funded by Movember and the Prostate Cancer Foundation of Australia and co-badged by the Australian and New Zealand Urological and Prostate Cancer Trials Group. The sponsor (Peter MacCallum Cancer Centre) and funders had no direct role in the study.

Acknowledgments: The authors wish to acknowledge the contribution of Professor Andrew Scott in initial discussions regarding the conceptualisation of the economic evaluation. MSH also acknowledges research funding from the Prostate Cancer Foundation and the Peter MacCallum Foundation.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi: https://doi.org/10.1016/j.eururo.2020.11.043.

References


